KYTHERA Biopharmaceuticals to Present at Leerink Swann 2012 Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference in New York City.

               

Event:

Leerink Swann 2012 Global Healthcare Conference

Date:

Wednesday, February 15, 2012

Time:

10:30 a.m. ET
 

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.



CONTACT:

KYTHERA Biopharmaceuticals, Inc.
Investor Contact: Heather Rowe
Tel: (818) 587-4559
[email protected]
or
Media Contact: Erica Bazerkanian
Tel: (805) 300-9289
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.